/Companies

Theromics

West Bridgewater, US · Founded 2016 · Delaware corporation · 2 known investors

Find your way into Theromics

Each arrow is one introduction. Sign up to fill in the first one.

257 people can intro you to Damian

Ask David Martirano to introduce you to Damian Dupuy

You →David · together at Brown University Health →Damian

181 people can intro you to Andrew

Ask Jamie Chen to introduce you to Andrew C. Zeringue

You →Jamie · together at Quantum Surgical →Andrew

Sign up to find every way you can get introduced to Theromics

  • Your email: who you already know at Theromics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Theromics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Theromics develops protein-based injectable nanogel accelerants (HeatSYNC and CryoSYNC) that improve energy transfer in soft tissue to make thermal ablation procedures larger, more spherical, and more effective, and to combine ablation with localized drug or immunotherapy delivery. It targets interventional oncology and conditions such as uterine fibroids, endometriosis, and breast cancer, and was spun out of Brown University.

Founders & leadership

Theromics was founded in 2016 by Damian Dupuy.

DDDamian Dupuy
Damian DupuyFounder · Chief Scientific OfficerDamian Dupuy is an executive at Theromics developing biopolymers with thermal properties for medical applications including interventional oncology, women's health, and drug delivery.
ACAndrew C. Zeringue
Andrew C. ZeringueChief Executive OfficerAndrew C. Zeringue is CEO of Theromics, a Brown University spinout developing injectable thermal ablation accelerants for interventional oncology procedures. With nearly two decades of experience in medical device commercialization, he previously worked on bringing multiple interventional oncology platforms to market including embolic agents, irreversible electroporation, microwave, radioembolization, and cryoablation systems.
WK
William Keun Chan ParkNamed on SEC filing
EW
Edward WalshNamed on SEC filing

Investors · 2

Funding

SEC filings, press & company announcements

$2.3M disclosed across 4 of 5 rounds · 2018–2023

▶$1.1MraisedMay 2023 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John BrooksDirector
  • Charles R. Williams, IIIDirector
  • Damian DupuyExecutive Officer, Director
  • Joseph AmaralDirector
  • Ronald MurphyExecutive Officer, Director
Offering amount
$2M
Amount sold
$1.1M
Minimum investment
$1
First sale
Apr 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedOct 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Keun Chan ParkExecutive Officer, Director
  • Joseph AmaralDirector
  • Ronald MurphyExecutive Officer, Director
  • Damian DupuyExecutive Officer, Director
Offering amount
$2M
Amount sold
$1M
Minimum investment
$1
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedAug 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Keun Chan ParkExecutive Officer, Director
  • Joseph AmaralDirector
  • Ronald MurphyExecutive Officer, Director
  • Damian DupuyExecutive Officer, Director
Offering amount
$1M
Amount sold
$125K
Minimum investment
$1
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Damian DupuyExecutive Officer, Director
  • William Keun Chan ParkExecutive Officer, Director
  • Edward WalshExecutive Officer, Director
Offering amount
$1M
Amount sold
$100K
Minimum investment
$1
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Companies working in the same space as Theromics.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase ISTTR2021$256K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Theromics do?
Theromics develops protein-based injectable nanogel accelerants (HeatSYNC and CryoSYNC) that improve energy transfer in soft tissue to make thermal ablation procedures larger, more spherical, and more effective, and to combine ablation with localized drug or immunotherapy delivery. It targets interventional oncology and conditions such as uterine fibroids, endometriosis, and breast cancer, and was spun out of Brown University.
Who founded Theromics?
Theromics was founded by Damian Dupuy in 2016.
Who are Theromics's investors?
Theromics's investors include Beacon Angels, Maroon Venture Partners Fund.
How much funding has Theromics raised?
Theromics has disclosed $2.3M raised across 4 of its 5 known rounds.
Where is Theromics headquartered?
Theromics is headquartered in West Bridgewater, US.